Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

85.38 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
71 72 Next >
WAINUA™ (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
From AstraZeneca
Via Business Wire
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
Which weight-loss stocks are good buys today? 
Via The Motley Fool
Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside
RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a burgeoning area in therapeutics following the green light for Novartis... 
Via Benzinga
COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs
COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023.&n 
Via Benzinga
Analyzing AstraZeneca In Comparison To Competitors In Pharmaceuticals Industry
 
Via Benzinga
Health Care Company AstraZeneca Announces Acquisition of Icosavax
 
Via Benzinga
Industry Comparison: Evaluating AstraZeneca Against Competitors In Pharmaceuticals Industry
 
Via Benzinga
Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today?
Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the  
Via Benzinga
Why Is Compugen (CGEN) Stock Up 189% Today?
Compugen stock is up on Tuesday as investors in CGEN shares react to an exclusive licensing agreement with Gilead Sciences. 
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Eagle Bulk Shipping Inc. (NYSE - EGLE), Icosavax, Inc. (Nasdaq - ICVX), Evofem Biosciences, Inc. (OTC - EVFM), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)
From Brodsky & Smith LLC
Via GlobeNewswire
These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?
2024 is going to be a sizzler in the biopharma sector. 
Via The Motley Fool
Can Altimmune's weight-loss drug be a game-changer?
The runaway success of weight-loss drugs like Novo Nordisk A/S (NYSE: NVO) Ozempic and Eli Lilly and Co. (NYSE: LLY) Mounjaro has kicked off a gold 
Via MarketBeat
Oracle's Falling, but You Won't Want to Miss This Soaring Biotech Stock
Tuesday brought favorable inflation data, and bullish investors are looking for stock winners. 
Via The Motley Fool
Topics Economy
Why Is Icosavax (ICVX) Stock Up 46% Today?
Icosavax stock is up on Tuesday as investors react to an acquisition deal with AstraZeneca that values ICVX between $15 and $20 per share. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Checking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading! 
Via InvestorPlace
AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data
From AstraZeneca
Via Business Wire
AstraZeneca To Acquire US Respiratory Vaccine Player Icosavax For Over $800M
AstraZeneca Plc (NASDAQ: AZN) has agreed to acquire Icosavax Inc (NASDAQ: ICVX) at $15.00 per share in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash,... 
Via Benzinga
Neurology Focused Pasithea Therapeutics Stock Soars Over 150% Today - Here's Why
Pasithea Therapeutics Corp (NASDAQ: KTTA) announced preclinical results from two in vivo studies evaluating the antitumor efficacy of PAS-004 in NRAS mutation  
Via Benzinga
AstraZeneca's Investigational Drug Shows Durable Clinical Benefit In Patients With Rare Blood Disease
AstraZeneca Plc (NASDAQ: AZN)  
Via Benzinga
Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis
From Alexion
Via Business Wire
AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?
It'll take a few years for its latest moves to pay off, assuming they do. 
Via The Motley Fool
Topics Artificial Intelligence
Is Now the Right Time to Buy AstraZeneca Stock?
The pharmaceutical giant is making strident moves to compete in hot markets, but it's not a cheap stock. 
Via The Motley Fool
Pharma Industry on Alert as Biden Administration Explores Patent Seizure Powers
The White House is endorsing a contentious power that permits the government to reclaim patents for specific  
Via Benzinga
Topics Intellectual Property
AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report
AstraZeneca plc (NASDAQ: AZN) has reportedly finalized a partnership deal valued at up to $247 million with Absci Corporation (NASDAQ: ABSI), a U.S.-based firm specializing in artificial intelligence... 
Via Benzinga
Topics Artificial Intelligence
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of... 
Via Talk Markets
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies... 
Via Benzinga
AstraZeneca Stops Two Lokelma Late-Stage Trials After Evaluating Potential Benefits
AstraZeneca Plc (NASDAQ: AZN) discontinued the STABILIZE- 
Via Benzinga
AstraZeneca advances scientific leadership in hematology at ASH 2023
From AstraZeneca
Via Business Wire
Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem
Beijing’s BeiGene acquired global rights to a preclinical novel cyclin-dependent kinase 2 (CDK2) inhibitor from Boston’s Ensem Therapeutics in a $1.3 billion agreement. Ensem will receive an upfront... 
Via Talk Markets
Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant
Could AstraZeneca be an under-rated buy right now? 
Via The Motley Fool
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
71 72 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.